Ekso Bionics (EKSO) 10-Q 10 May 16 2016 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2016	May. 05, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Entity Registrant Name	EKSO BIONICS HOLDINGS, INC.
Entity Central Index Key	1,549,084
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	PNMD
Entity Common Stock, Shares Outstanding		16,182,889

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash	$ 12,314	$ 19,552
Accounts receivable	2,383	2,069
Inventories, net	2,531	1,056
Prepaid expenses and other current assets	738	436
Deferred cost of revenue, current	255	2,088
Total current assets	18,221	25,201
Property and equipment, net	2,617	2,625
Deferred cost of revenue	0	2,502
Intangible assets, net	1,431	1,584
Goodwill	189	189
Other assets	93	97
Total assets	22,551	32,198
Current liabilities:
Accounts payable	3,618	2,694
Accrued liabilities	2,928	1,885
Deferred revenues, current	1,222	3,960
Capital lease obligation, current	81	80
Total current liabilities	7,849	8,619
Deferred revenues	766	4,613
Warrant liability	6,210	9,195
Contingent consideration liability	768	768
Other non-current liabilities	205	195
Total liabilities	$ 15,798	$ 23,390
Commitments and contingencies (Note 12)
Stockholders' equity:
Convertible preferred stock, $0.001 par value; 10,000 shares authorized at March 31, 2016 and December 31, 2015; 9 and 13 outstanding at March 31, 2016 and December 31, 2015, respectively	$ 0	$ 0
Common stock, $0.001 par value; 71,429 shares authorized at March 31, 2016 and December 31, 2015; 15,604 and 15,027 outstanding at March 31, 2016 and December 31, 2015, respectively	109	105
Additional paid-in capital	101,686	100,094
Accumulated deficit	(95,042)	(91,391)
Total stockholders' equity	6,753	8,808
Total liabilities and stockholders' equity	$ 22,551	$ 32,198

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets [Parenthetical] - $ / shares shares in Thousands	Mar. 31, 2016	Dec. 31, 2015
Convertible Preferred stock, par value per share	$ 0.001	$ 0.001
Convertible Preferred stock, shares authorized	10,000	10,000
Convertible Preferred stock, shares issued	9	13
Convertible Preferred stock, shares outstanding	9	13
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	71,429	71,429
Common Stock, Shares, Issued	15,604	15,027
Common Stock, Shares, Outstanding	15,604	15,027

Condensed Consolidated Statemen

Condensed Consolidated Statement of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenue:
Medical devices (see Note 2)	$ 8,057	$ 985
Engineering services	429	704
Total revenue	8,486	1,689
Cost of revenue:
Medical devices	6,669	798
Engineering services	319	488
Total cost of revenue	6,988	1,286
Gross profit	1,498	403
Operating expenses:
Sales and marketing	2,503	1,851
Research and development	2,149	983
General and administrative	3,488	1,662
Total operating expenses	8,140	4,496
Loss from operations	(6,642)	(4,093)
Other income (expense) net:
Gain on warrant liability	2,985	0
Interest and other, net	6	(22)
Total other income (expense), net	2,991	(22)
Net loss	(3,651)	(4,115)
Less: Preferred deemed dividend	(3,124)	0
Net loss applicable to common shareholders	$ (6,775)	$ (4,115)
Basic and diluted net loss per share (In dollars per share)	$ (0.44)	$ (0.28)
Weighted average number of shares of common stock outstanding, basic and diluted	15,388	14,542

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Operating activities:
Net loss	$ (3,651)	$ (4,115)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	440	200
Inventory allowance expense	0	45
Amortization of deferred rent	(9)	(10)
Stock-based compensation expense	1,574	349
(Gain) on change in fair value of warrant liability	(2,985)	0
Changes in operating assets and liabilities:
Accounts receivable	(314)	94
Inventories	(1,475)	(261)
Prepaid expense and other assets	(298)	(59)
Deferred costs of revenue	4,335	(354)
Accounts payable	924	681
Accrued liabilities	1,255	(721)
Deferred revenues	(6,585)	323
Net cash used in operating activities	(6,789)	(3,828)
Investing activities:
Acquisition of property and equipment	(285)	(281)
Net cash used in investing activities	(285)	(281)
Financing activities:
Principal payments on note payable	(19)	(11)
Fees paid related to 2015 issuance of convertible preferred stock	(173)	0
Proceeds from exercise of stock options	28	31
Proceeds from exercise of warrants	0	32
Net cash (used in) provided by financing activities	(164)	52
Net decrease in cash	(7,238)	(4,057)
Cash at beginning of period	19,552	25,190
Cash at end of period	$ 12,314	$ 21,133

Organization

Organization	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	1. Organization Description of Business On January 15, 2014, a wholly-owned subsidiary of Ekso Bionics Holdings, Inc. named Ekso Acquisition Corp. merged with and into Ekso Bionics, Inc. (the “Merger”). Ekso Bionics, Inc. was the surviving corporation and became a wholly-owned subsidiary of Ekso Bionics Holdings, Inc. As a result of this transaction, Ekso Bionics Holdings, Inc. discontinued its pre-merger operations, acquired the business of Ekso Bionics, Inc. and continues the operations of Ekso Bionics, Inc. as a publicly traded company. Ekso Bionics, Inc. was incorporated in January 2005 in the State of Delaware. As used in these notes to the consolidated financial statements, the term “the Company” refers to Ekso Bionics Holdings, Inc. formerly known as PN Med Group, Inc., and its wholly-owned subsidiaries, including Ekso Bionics, Inc. after giving effect to the Merger; the term “Holdings” refers to the business of Ekso Bionics Holdings, Inc. prior to the Merger, and the term “Ekso Bionics” refers to Ekso Bionics, Inc. prior to the Merger. Unless otherwise indicated, all dollar and share amounts included in these notes to the financial statements are in thousands. All common stock share and per share amounts have been retroactively adjusted to reflect the one-for-seven reverse stock split completed on May 4, 2016. See Note 15, Subsequent Event The Company designs, develops, and sells exoskeletons that augment human strength, endurance and mobility. The Company’s exoskeletons have applications in health care, industrial, military, and consumer markets. Liquidity Largely as a result of significant research and development activities related to the development of the Company’s advanced technology and commercialization of this technology into its medical device business, the Company has incurred significant operating losses and negative cash flows from operations since inception. The Company has also recognized significant non-cash losses associated with the revaluation of certain securities, which have also contributed significantly to its accumulated deficit. As of March 31, 2016, the Company had an accumulated deficit of $ 95,042 Cash on hand at March 31, 2016 was $ 12,314 19,552 6,789 3,828 Based upon the Company’s current twelve-month average net use of cash of approximately $ 1,800 The Company’s actual capital requirements may vary significantly and will depend on many factors. For example, the Company plans to continue to increase its investments (i) in its clinical, sales and marketing initiatives to accelerate adoption of the Ekso robotic exoskeleton in the rehabilitation market, (ii) in its research, development and commercialization activities with respect to an Ekso robotic exoskeleton for home use, and/or (iii) in the development and commercialization of able-bodied exoskeletons for industrial use. Consequently, the Company will require significant additional financing in the future, which the Company intends to raise by the end of the year through corporate collaborations, public or private equity offerings, debt financings or warrant solicitations. Sales of additional equity securities by us could result in the dilution of the interests of existing stockholders. There can be no assurance that financing will be available when required in sufficient amounts, on acceptable terms or at all. In the event that the necessary additional financing is not obtained, the Company may be required to reduce its discretionary overhead costs substantially, including research and development, general and administrative, and sales and marketing expenses or otherwise curtail operations.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies and Estimates	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies and Estimates	2. Basis of Presentation and Summary of Significant Accounting Policies and Estimates These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”), for the presentation of interim financial information. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed, or omitted, pursuant to such rules and regulations. The condensed consolidated balance sheet at December 31, 2015, has been derived from the audited consolidated financial statements at that date but does not include all disclosures required for the annual financial statements and should be read in conjunction with our audited consolidated financial statements and notes thereto included as part of our Annual Report on Form 10-K for the year ended December 31, 2015. Unless otherwise indicated, all dollar and share amounts (excluding per share amounts) included in these notes to the financial statements are in thousands. In management’s opinion, the condensed consolidated financial statements reflect all adjustments (including reclassifications and normal recurring adjustments) necessary to present fairly the financial position at March 31, 2016, and results of operations and cash flows for all periods presented. The interim results presented are not necessarily indicative of results that can be expected for a full year. The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to: revenue recognition, deferred revenue and the deferral of the associated costs, future warranty costs, maintenance and planned improvement costs associated with medical device units sold prior to 2016, useful lives assigned to long-lived assets, realizability of deferred tax assets, the valuation of options and warrants, and contingencies. Actual results could differ from those estimates. Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash and accounts receivable. We maintain our cash accounts in excess of federally insured limits. However, we believe we are not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. We extend credit to customers in the normal course of business and perform ongoing credit evaluations of our customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the consolidated financial statements. We do not require collateral from our customers to secure accounts receivable. Accounts receivable are derived from the sale of products shipped and services performed for customers located in the U.S. and throughout the world. Invoices are aged based on contractual terms with the customer. We review accounts receivable for collectability and provide an allowance for credit losses, as needed. We have not experienced any material losses related to accounts receivable as of March 31, 2016 and December 31, 2015. Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. We do not enter into any foreign currency hedging agreements and are susceptible to gains and losses from foreign currency fluctuations. To date, we have not experienced significant gains or losses upon settling foreign currency denominated accounts receivable. As of March 31, 2016, we had one customer with accounts receivable balances totaling 10 16 10 In the three months ended March 31, 2016, we had four customers with billed revenue of 10 27 20 11 10 17 16 The Company builds medical device robotic exoskeletons for sale and capitalizes into inventory materials, direct and indirect labor and overhead in connection with manufacture and assembly of these units. When the Company brought its first version medical device to market in 2012, the Company could not be certain as to the costs it would incur to support, maintain, service and upgrade these early stage devices. Primarily for this reason, prior to January 1, 2016, the sale of a device, associated software, initial training, and extended support and maintenance were deemed as a single unit of accounting due to the uncertainty of the Company’s follow-up maintenance and upgrade expenses, which were forecast to extend over three years. Accordingly, the revenue from the sales of the device and associated cost of revenue were deferred at the time of shipment. Upon completion of training, such amounts were recognized as revenue and cost of revenue over a three year period on a straight line basis, while all service expenses, whether or not covered by the Company’s original warranty, extended warranty contracts, or neither, were recognized as incurred. Effective January 1, 2016, the Company determined it had established (i) separate individual pricing for training, extended warranty coverage, and out-of-contract service or repairs, (ii) sufficient historical evidence of customer buying patterns for extended warranty and maintenance coverage, and (iii) a basis for estimating and recording warranty and service costs, to allow the Company to bifurcate its sales transactions into two separate units of accounting: (1) the device, associated software, original manufacturer warranty and training if required, and (2) extended support and maintenance. The Company has therefore now begun to recognize revenue related to its sales transactions on a multiple element approach in which revenue is recognized upon the delivery of the separate elements to the customer. Revenue relating to the undelivered elements is deferred using the relative selling price method, which allocates revenue to each element using the estimated selling prices for the deliverables when vendor-specific objective evidence or third-party evidence is not available. For sales beginning January 1, 2016, revenue and associated cost of revenue of medical devices will be recognized when delivered, or training has been completed, if required. Revenue for extended maintenance and support agreements will be recognized on a straight line basis over the contractual term of the agreement, which typically ranges from one to four years. Consistent with this change, the Company recognized medical device revenue previously deferred at December 31, 2015 of $ 6,517 4,159 2,358 212 911 In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-09 Compensation – Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date Revenue from Contracts with Customers (Topic 606) Identifying Performance Obligations and Licensing

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. Fair Value Measurements Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Three levels of inputs, of which the first two are considered observable and the last unobservable, may be used to measure fair value which are the following: • Level 1 • Level 2 • Level 3 Quoted Prices in Significant Active Markets Other Significant For Identical Observable Unobservable Items Inputs Inputs Total (Level 1) (Level 2) (Level 3) March 31, 2016 Liabilities Warrant liability $ (6,210) $ - $ - $ (6,210) Contingent consideration liability $ (768) $ - $ - $ (768) December 31, 2015 Liabilities Warrant liability $ (9,195) $ - $ - $ (9,195) Contingent consideration liability $ (768) $ - $ - $ (768) Warrant Contingent Balance at December 31, 2015 $ (9,195) $ (768) Gain on decrease in fair value of warrants issued with 2015 financing 2,985 - Balance at March 31, 2016 $ (6,210) (768) Refer to Note 9. Capitalization and Equity Structure – Warrants

Deferred Revenues

Deferred Revenues	3 Months Ended
	Mar. 31, 2016
Deferred Revenue Disclosure [Abstract]
Deferred Revenues	4. Deferred Revenues In connection with our medical device sales and engineering services, we often receive cash payments before our earnings process is complete. In these instances, we record the payments as customer deposits until a device is shipped to the customer, or as customer advances in the case of engineering services until the earnings process is achieved. In both cases, the cash received is recorded as a component of deferred revenue. As described in Note 2. Summary of Significant Accounting Policies and Estimates, Medical Device Revenue and Cost of Revenue Recognition 6,517 4,159 March 31 December 31, Customer deposits and advances $ 47 $ 48 Deferred medical device revenues 551 7,388 Deferred rental income 64 71 Deferred extended maintenance and support 1,326 1,066 Total deferred revenues 1,988 8,573 Less current portion (1,222) (3,960) Deferred revenues, non-current 766 4,613 Deferred medical device unit costs $ 255 $ 4,590 Less current portion (255) (2,088) Deferred cost of revenue, non-current $ - $ 2,502

Intangible Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	5. Intangible Assets On December 1, 2015, the Company acquired substantially all of the assets of Equipois, LLC, a New Hampshire limited liability company, for an initial payment of $ 1,071 768 1,610 Cost Accumulated Net Developed technology $ 1,160 $ (129) $ 1,031 Customer relationships 70 (8) 62 Customer trade name 380 (42) 338 $ 1,610 $ (179) $ 1,431 Estimated future amortization for the remainder of 2016 is $ 404 537 490

Accrued Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2016
Accrued Liabilities and Other Liabilities [Abstract]
Accrued Liabilities	6. Accrued Liabilities March 31, December 31, 2016 2015 Salaries, benefits and related expenses $ 1,563 $ 1,464 Maintenance 911 - Warranty expense 216 - Professional fees 158 257 Other 80 164 Total $ 2,928 $ 1,885

Maintenance and Warranty

Maintenance and Warranty	3 Months Ended
	Mar. 31, 2016
Maintenance And Warranty [Abstract]
Maintenance and Warranty	7. Maintenance and Warranty Sales of devices generally include an initial warranty for parts and services for one year in the U.S. and two years in Europe, the Middle East and Africa. During the quarter ended March 31, 2016, the Company determined it had sufficient historical experience of warranty costs to estimate future costs for devices sold. As a result, and beginning during the quarter ended March 31, 2016, a liability for the estimated cost of product warranty is established at the time revenue is recognized based on the historical experience of known product failure rates and expected material and labor costs to provide warranty services. From time to time, specific additional warranty accruals may be made if unforeseen technical problems arise. Alternatively, if estimates are determined to be greater than the actual amounts necessary, a portion of the liability may be reversed in future periods. Warranty costs are reflected in the condensed consolidated statement of operations as a component of costs of revenue. In addition, for the quarter ended March 31, 2016, the Company recorded a one-time charge of $ 911 2016 Maintenance Warranty Total Balance at December 31, 2015 $ - $ - $ - Additions for estimated future expense 911 255 1,166 Incurred costs - - - Other - - - Balance at March 31, 2016 $ 911 $ 255 $ 1,166 Current portion 911 216 1,127 Long-term portion - 39 39 Total $ 911 $ 255 $ 1,166 2015 Maintenance Warranty Total Balance at December 31, 2014 $ - $ 126 $ 126 Additions for estimated future expense - - - Incurred costs - (17) (17) Other - - - Balance at March 31, 2015 $ - $ 109 $ 109 Current portion - 109 109 Long-term portion - - - Total $ - $ 109 $ 109 The long-term portion of warranty accrual is included as a component of Other long-term liabilities in the condensed consolidated balance sheets.

Lease and Note Obligations

Lease and Note Obligations	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Lease and Note Obligations	8. Lease and Note Obligations On November 29, 2011, the Company entered into an operating lease agreement for its headquarters and manufacturing facility in Richmond, California. The lease term commenced in March 2012 and expires in May 2017. The lease provides the Company with one option to renew for five additional years. The Company also leases nominal office space in Germany. In 2012, the Company entered into a note agreement in connection with the lease for its Richmond, California facility. The note, for an aggregate principal of $ 200 7 4 May 31, 2017 Commencing in August 2015, the Company entered into a long-term capital lease obligation for equipment. The aggregate principal of the lease is $ 166 4.7 3 July 1, 2020 Period Operating Note Capital Total 2016 - remainder $ 350 $ 36 $ 32 $ 68 2017 248 20 40 60 2018 91 - 37 37 2019 91 - 37 37 2020 89 - 22 22 Total minimum payments $ 869 56 168 224 Less interest (2) (16) (18) Present value minimum payments 54 152 206 less current portion (45) (36) (81) Long-term portion $ 9 $ 116 $ 125 Rent expense under the Company’s operating leases was $ 96 86

Capitalization and Equity Struc

Capitalization and Equity Structure	3 Months Ended
	Mar. 31, 2016
Stockholders' Equity Note [Abstract]
Capitalization and Equity Structure	9. Capitalization and Equity Structure Refer to Note 15, Subsequent Event Summary: The Company’s authorized capital stock at March 31, 2016 consisted of 71,429 10,000 15,604 9 Convertible Preferred Stock: In December 2015, the Company issued 15 2,122 15,000 13 4 566 7.07 3,124 7,221 Warrants Source Exercise Term At December 31, At March 31, 2015 Series A Preferred warrants $ 8.75 5 2,122 2,122 2014 PPO and Merger Placement agent warrants $ 7.00 5 426 426 Bridge warrants $ 7.00 3 371 371 PPO warrants $ 14.00 5 1,078 1,078 Pre 2014 warrants $ 9.66 various 88 88 4,085 4,085 In connection with the December 2015 issuance of convertible preferred stock mentioned above, the Company issued warrants to purchase up to an aggregate of 2,122 5 8.75 Current share price $ 5.25 Conversion price $ 8.75 Risk-free interest rate 1.16 % Periodic rate 0.55 % Term (years) 4.73 Volatility of stock 75 % The warrants were valued at $ 9,195 2,985

Stock-based Compensation

Stock-based Compensation	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation	10. Stock-based Compensation Refer to Note 15, Subsequent Event The Company’s Amended and Restated 2014 Equity Incentive Plan (the “2014 Plan”) allows for the issuance of an aggregate of 3,714 1,480 The following table summarizes information about the Company’s stock options outstanding at March 31, 2016, and activity during the three-month period then ended: Weighted- Average Weighted- Remaining Average Contractual Aggregate Stock Exercise Life Intrinsic Awards Price (Years) Value Balance as of December 31, 2015 1,963 $ 7.09 Options granted 145 $ 5.55 Options exercised (10) $ 2.73 Options forfeited (110) $ 8.41 Options cancelled (9) $ 10.11 Balance as of March 31, 2016 1,979 6.91 7.00 1,522 Vested and expected to vest at March 31, 2016 1,851 6.85 1,518 Exercisable as of March 31, 2016 1,062 5.23 1,464 As of March 31, 2016, total unrecognized compensation cost related to unvested stock options was $ 4,640 2.8 The per-share fair value of each stock option was determined on the date of grant using the Black-Scholes option pricing model using the following assumptions: Three months ended March 31, 2016 2015 Dividend yield — — Risk-free interest rate 1.24% - 1.78 % 1.41% - 1.92 % Expected term (in years) 5-10 6-10 Volatility 77 % 73 % Total stock-based compensation expense related to options granted to employees and non-employees was included in the Condensed Consolidated Statements of Operations as follows: Three months ended March 31, 2016 2015 Sales and marketing $ 232 $ 132 Research and development 231 54 General and administrative 1,111 163 $ 1,574 $ 349 In conjunction with the resignation of the Company’s then Chief Executive Officer in February 2016, the Company accelerated the vesting of options that would have vested in the subsequent twelve months and extended the exercise period of the resulting shares from three months to six years. In addition, the Company extended the exercise period for an employee that was terminated in March 2016 from three months to one year. These modifications resulted in incremental stock compensation expense of $ 59 774

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	11. Income Taxes There were no material changes to the unrecognized tax benefits in the three months ended March 31, 2016, and the Company does not expect significant changes to unrecognized tax benefits through the end of the fiscal year. Because of the Company’s history of tax losses, all years remain open to tax audit.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	12. Commitments and Contingencies Contingencies In the normal course of business, the Company is subject to various legal matters. In the opinion of management, the resolution of such matters will not have a material adverse effect on the Company’s condensed consolidated financial statements. Material Contracts The Company enters into various license, research collaboration and development agreements which provide for payments to the Company for government grants, fees, cost reimbursements typically with a markup, technology transfer and license fees, and royalty payments on sales. The Company has two license agreements to maintain exclusive rights to patents. The Company is also required to pay 1 21 1 50 In connection with acquisition of Equipois, the Company assumed the rights and obligations of Equipois under a license agreement with Garrett Brown, the developer of certain intellectual property related to mechanical balance and support arm technologies, which grants us an exclusive license with respect to the technology and patent rights for certain fields of use. Pursuant to the terms of the license agreement, the Company will be required to pay Mr. Brown a single-digit royalty on net receipts, subject to a $ 50 The Company entered into a supply agreement with Equipois to purchase mechanical arm products on a quarterly basis commencing on December 1, 2015 through December 31, 2016, with a minimum annual price of $ 157 U.S. Food and Drug Administration Clearance On April 4, 2016, the Company received clearance from the U.S. Food and Drug Administration (“FDA”) to market its Ekso GT robotic exoskeleton for use in the treatment of individuals with hemiplegia due to stroke, individuals with spinal cord injuries at levels T4 to L5, and individuals with spinal cord injuries at levels of T3 to C7 (ASIA D), in accordance with the device’s labeling. The Company believes that prior to April 4, 2016, the Company’s Ekso GT robotic exoskeleton had been appropriately marketed in the United States as a Class I 510(k) exempt Powered Exercise Equipment device since February 2012. On June 26, 2014, the FDA announced the creation of a new product classification for Powered Exoskeleton devices. On October 21, 2014, the FDA published the summary for the new Powered Exoskeleton classification and designated it as being Class II, which requires the clearance of a 510(k) notice. On October 21, 2014, concurrent with the FDA’s publication of the reclassification of Powered Exoskeleton devices, the FDA issued the Company an “Untitled Letter” which informed the Company in writing of the agency’s belief that this new product classification applied to the Ekso GT device. On December 24, 2014, the Company filed a 510(k) notice for the Ekso robotic exoskeleton which was accepted by the FDA for substantive review on July 29, 2015. As discussed above, the Company received FDA clearance to market the Ekso GT in accordance with the devise’s labeling on April 4, 2016. From September 2, 2015 to September 11, 2015, the Division of Bioresearch Monitoring Center for Devices and Radiological Health of the FDA conducted an inspection of the Company’s facility in Richmond, California. At the conclusion of the inspection, the FDA issued a Form FDA 483 with four observations. These observations were inspectional and did not represent a final FDA determination of non-compliance. The observations pertained to informed consent requirements, reporting of adverse results and records maintenance. On October 2, 2015, the Company responded to the FDA describing the corrective and preventive actions that the Company had implemented and continued to implement to address the FDA’s concerns.

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Net Loss Per Share	13. Net Loss Per Share Refer to Note 15, Subsequent Event The following table sets forth the computation of basic and diluted net loss per share: Three months ended March 31, 2016 2015 Numerator: Net loss applicable to common stockholders, basic and diluted $ (6,775) $ (4,115) Denominator Weighted-average number of shares, basic and diluted 15,388 14,542 Net loss per share, basic and diluted $ (0.44) $ (0.28) Recognition of previously deferred revenue and cost of goods in the quarter ended March 31, 2016 as described in Note 2. Summary of Significant Accounting Policies and Estimates, Medical Device Revenue and Cost of Revenue Recognition 2,358 0.15 March 31, 2016 2015 Options to purchase common stock 1,979 1,496 Warrants for common stock 4,085 1,966 Common stock issuable upon conversion of preferred shares 1,309 - Total common stock equivalents 7,373 3,462

Segment Disclosures

Segment Disclosures	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Segment Disclosures	14. Segment Disclosures The Company has two reportable segments, Engineering Services and Medical Devices. Engineering Services generates revenue principally from collaborative research and development service arrangements, technology license agreements, and government grants where the Company uses its robotics domain knowledge in bionic exoskeletons to bid on and procure contracts and grants from entities such as such as the National Science Foundation and the Defense Advanced Research Projects Agency. The Medical Devices segment designs, engineers, and manufactures exoskeletons for applications in the medical and military markets. The Company evaluates performance and allocates resources based on segment gross profit margin. The reportable segments are each managed separately because they serve distinct markets, and one segment provides a service and the other manufactures and distributes a unique product. The Company does not consider net assets as a segment measure and, accordingly, assets are not allocated. Medical Engineering Devices Services Total Three months ended March 31, 2016 Revenue $ 8,057 $ 429 $ 8,486 Cost of revenue 6,669 319 6,988 Gross profit $ 1,388 $ 110 $ 1,498 Three months ended March 31, 2015 Revenue $ 985 $ 704 $ 1,689 Cost of revenue 798 488 1,286 Gross profit $ 187 $ 216 $ 403 Three Months Ended March 31, 2016 2015 North America $ 4,521 $ 1,271 All Other 3,965 418 $ 8,486 $ 1,689

Subsequent Event - Reverse Stoc

Subsequent Event - Reverse Stock Split	3 Months Ended
	Mar. 31, 2016
Subsequent Events [Abstract]
Subsequent Events [Text Block]	15. Subsequent Event – Reverse Stock Split After the close of the stock market on May 4, 2016, the Company effected a 1-for-7 reverse split .

Basis of Presentation and Sum21

Basis of Presentation and Summary of Significant Accounting Policies and Estimates (Policies)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”), for the presentation of interim financial information. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed, or omitted, pursuant to such rules and regulations. The condensed consolidated balance sheet at December 31, 2015, has been derived from the audited consolidated financial statements at that date but does not include all disclosures required for the annual financial statements and should be read in conjunction with our audited consolidated financial statements and notes thereto included as part of our Annual Report on Form 10-K for the year ended December 31, 2015. Unless otherwise indicated, all dollar and share amounts (excluding per share amounts) included in these notes to the financial statements are in thousands. In management’s opinion, the condensed consolidated financial statements reflect all adjustments (including reclassifications and normal recurring adjustments) necessary to present fairly the financial position at March 31, 2016, and results of operations and cash flows for all periods presented. The interim results presented are not necessarily indicative of results that can be expected for a full year. The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to: revenue recognition, deferred revenue and the deferral of the associated costs, future warranty costs, maintenance and planned improvement costs associated with medical device units sold prior to 2016, useful lives assigned to long-lived assets, realizability of deferred tax assets, the valuation of options and warrants, and contingencies. Actual results could differ from those estimates.
Concentration of Credit Risk and Other Risks and Uncertainties	Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash and accounts receivable. We maintain our cash accounts in excess of federally insured limits. However, we believe we are not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. We extend credit to customers in the normal course of business and perform ongoing credit evaluations of our customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the consolidated financial statements. We do not require collateral from our customers to secure accounts receivable. Accounts receivable are derived from the sale of products shipped and services performed for customers located in the U.S. and throughout the world. Invoices are aged based on contractual terms with the customer. We review accounts receivable for collectability and provide an allowance for credit losses, as needed. We have not experienced any material losses related to accounts receivable as of March 31, 2016 and December 31, 2015. Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. We do not enter into any foreign currency hedging agreements and are susceptible to gains and losses from foreign currency fluctuations. To date, we have not experienced significant gains or losses upon settling foreign currency denominated accounts receivable. As of March 31, 2016, we had one customer with accounts receivable balances totaling 10 16 10 In the three months ended March 31, 2016, we had four customers with billed revenue of 10 27 20 11 10 17 16
Revenue and Cost of Revenue Recognition	Medical Device Revenue and Cost of Revenue Recognition The Company builds medical device robotic exoskeletons for sale and capitalizes into inventory materials, direct and indirect labor and overhead in connection with manufacture and assembly of these units. When the Company brought its first version medical device to market in 2012, the Company could not be certain as to the costs it would incur to support, maintain, service and upgrade these early stage devices. Primarily for this reason, prior to January 1, 2016, the sale of a device, associated software, initial training, and extended support and maintenance were deemed as a single unit of accounting due to the uncertainty of the Company’s follow-up maintenance and upgrade expenses, which were forecast to extend over three years. Accordingly, the revenue from the sales of the device and associated cost of revenue were deferred at the time of shipment. Upon completion of training, such amounts were recognized as revenue and cost of revenue over a three year period on a straight line basis, while all service expenses, whether or not covered by the Company’s original warranty, extended warranty contracts, or neither, were recognized as incurred. Effective January 1, 2016, the Company determined it had established (i) separate individual pricing for training, extended warranty coverage, and out-of-contract service or repairs, (ii) sufficient historical evidence of customer buying patterns for extended warranty and maintenance coverage, and (iii) a basis for estimating and recording warranty and service costs, to allow the Company to bifurcate its sales transactions into two separate units of accounting: (1) the device, associated software, original manufacturer warranty and training if required, and (2) extended support and maintenance. The Company has therefore now begun to recognize revenue related to its sales transactions on a multiple element approach in which revenue is recognized upon the delivery of the separate elements to the customer. Revenue relating to the undelivered elements is deferred using the relative selling price method, which allocates revenue to each element using the estimated selling prices for the deliverables when vendor-specific objective evidence or third-party evidence is not available. For sales beginning January 1, 2016, revenue and associated cost of revenue of medical devices will be recognized when delivered, or training has been completed, if required. Revenue for extended maintenance and support agreements will be recognized on a straight line basis over the contractual term of the agreement, which typically ranges from one to four years. Consistent with this change, the Company recognized medical device revenue previously deferred at December 31, 2015 of $ 6,517 4,159 2,358 212 911
Recent Accounting Pronouncements	Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-09 Compensation – Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date Revenue from Contracts with Customers (Topic 606) Identifying Performance Obligations and Licensing

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The Company’s fair value hierarchies for its financial assets and liabilities which require fair value measurement are as follows: Quoted Prices in Significant Active Markets Other Significant For Identical Observable Unobservable Items Inputs Inputs Total (Level 1) (Level 2) (Level 3) March 31, 2016 Liabilities Warrant liability $ (6,210) $ - $ - $ (6,210) Contingent consideration liability $ (768) $ - $ - $ (768) December 31, 2015 Liabilities Warrant liability $ (9,195) $ - $ - $ (9,195) Contingent consideration liability $ (768) $ - $ - $ (768)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities for the three month period ended March 31, 2016, which were measured at fair value on a recurring basis: Warrant Contingent Balance at December 31, 2015 $ (9,195) $ (768) Gain on decrease in fair value of warrants issued with 2015 financing 2,985 - Balance at March 31, 2016 $ (6,210) (768)

Deferred Revenues (Tables)

Deferred Revenues (Tables)	3 Months Ended
	Mar. 31, 2016
Deferred Revenue Disclosure [Abstract]
Schedule of Deferred Revenue	Deferred revenues and deferred cost of revenues consist of the following: March 31 December 31, Customer deposits and advances $ 47 $ 48 Deferred medical device revenues 551 7,388 Deferred rental income 64 71 Deferred extended maintenance and support 1,326 1,066 Total deferred revenues 1,988 8,573 Less current portion (1,222) (3,960) Deferred revenues, non-current 766 4,613 Deferred medical device unit costs $ 255 $ 4,590 Less current portion (255) (2,088) Deferred cost of revenue, non-current $ - $ 2,502

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of Purchased Intangible Assets	The following table reflects the amortization of the purchased intangible assets as of March 31, 2016: Cost Accumulated Net Developed technology $ 1,160 $ (129) $ 1,031 Customer relationships 70 (8) 62 Customer trade name 380 (42) 338 $ 1,610 $ (179) $ 1,431

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2016
Accrued Liabilities and Other Liabilities [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consist of the following: March 31, December 31, 2016 2015 Salaries, benefits and related expenses $ 1,563 $ 1,464 Maintenance 911 - Warranty expense 216 - Professional fees 158 257 Other 80 164 Total $ 2,928 $ 1,885

Maintenance and Warranty (Table

Maintenance and Warranty (Tables)	3 Months Ended
	Mar. 31, 2016
Maintenance And Warranty [Abstract]
Reconciliation of Changes in Maintenance and Warranty Liabilities	A reconciliation of the changes in the maintenance and warranty liabilities for the periods ended March 31, 2016 and 2015 are as follows: 2016 Maintenance Warranty Total Balance at December 31, 2015 $ - $ - $ - Additions for estimated future expense 911 255 1,166 Incurred costs - - - Other - - - Balance at March 31, 2016 $ 911 $ 255 $ 1,166 Current portion 911 216 1,127 Long-term portion - 39 39 Total $ 911 $ 255 $ 1,166 2015 Maintenance Warranty Total Balance at December 31, 2014 $ - $ 126 $ 126 Additions for estimated future expense - - - Incurred costs - (17) (17) Other - - - Balance at March 31, 2015 $ - $ 109 $ 109 Current portion - 109 109 Long-term portion - - - Total $ - $ 109 $ 109

Lease and Note Obligations (Tab

Lease and Note Obligations (Tables)	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Schedule of Maturities of Future Obligations	The Company estimates future minimum payments as of March 31, 2016 to be the following: Period Operating Note Capital Total 2016 - remainder $ 350 $ 36 $ 32 $ 68 2017 248 20 40 60 2018 91 - 37 37 2019 91 - 37 37 2020 89 - 22 22 Total minimum payments $ 869 56 168 224 Less interest (2) (16) (18) Present value minimum payments 54 152 206 less current portion (45) (36) (81) Long-term portion $ 9 $ 116 $ 125

Capitalization and Equity Str28

Capitalization and Equity Structure (Tables)	3 Months Ended
	Mar. 31, 2016
Schedule of Warrant share activity	Warrant share activity for the three-month period ended March 31, 2016 is as follows: Source Exercise Term At December 31, At March 31, 2015 Series A Preferred warrants $ 8.75 5 2,122 2,122 2014 PPO and Merger Placement agent warrants $ 7.00 5 426 426 Bridge warrants $ 7.00 3 371 371 PPO warrants $ 14.00 5 1,078 1,078 Pre 2014 warrants $ 9.66 various 88 88 4,085 4,085
2016 Warrants [Member]
Schedule of assumption used in valuation	The following assumptions were used in the Binomial Lattice Option Pricing Model to measure the fair value of the embedded anti-dilution feature in the warrants as of March 31, 2016: Current share price $ 5.25 Conversion price $ 8.75 Risk-free interest rate 1.16 % Periodic rate 0.55 % Term (years) 4.73 Volatility of stock 75 %

Stock-based Compensation (Table

Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Stock Option Activity	The following table summarizes information about the Company’s stock options outstanding at March 31, 2016, and activity during the three-month period then ended: Weighted- Average Weighted- Remaining Average Contractual Aggregate Stock Exercise Life Intrinsic Awards Price (Years) Value Balance as of December 31, 2015 1,963 $ 7.09 Options granted 145 $ 5.55 Options exercised (10) $ 2.73 Options forfeited (110) $ 8.41 Options cancelled (9) $ 10.11 Balance as of March 31, 2016 1,979 6.91 7.00 1,522 Vested and expected to vest at March 31, 2016 1,851 6.85 1,518 Exercisable as of March 31, 2016 1,062 5.23 1,464
Schedule of Fair Value Calculation Assumptions	The per-share fair value of each stock option was determined on the date of grant using the Black-Scholes option pricing model using the following assumptions: Three months ended March 31, 2016 2015 Dividend yield — — Risk-free interest rate 1.24% - 1.78 % 1.41% - 1.92 % Expected term (in years) 5-10 6-10 Volatility 77 % 73 %
Allocation of Stock Option Compensation Expense	Total stock-based compensation expense related to options granted to employees and non-employees was included in the Condensed Consolidated Statements of Operations as follows: Three months ended March 31, 2016 2015 Sales and marketing $ 232 $ 132 Research and development 231 54 General and administrative 1,111 163 $ 1,574 $ 349

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Schedule of basic and diluted net income (loss) per share	The following table sets forth the computation of basic and diluted net loss per share: Three months ended March 31, 2016 2015 Numerator: Net loss applicable to common stockholders, basic and diluted $ (6,775) $ (4,115) Denominator Weighted-average number of shares, basic and diluted 107,718 101,791 Net loss per share, basic and diluted $ (0.06) $ (0.04)
Schedule of Antidilutive Securities	The following table sets forth potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented: March 31, 2016 2015 Options to purchase common stock 1,979 1,496 Warrants for common stock 4,085 1,966 Common stock issuable upon conversion of preferred shares 1,309 - Total common stock equivalents 7,373 3,462

Segment Disclosures (Tables)

Segment Disclosures (Tables)	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Schedule of Segment Reporting Information	Segment reporting information is as follows: Medical Engineering Devices Services Total Three months ended March 31, 2016 Revenue $ 8,057 $ 429 $ 8,486 Cost of revenue 6,669 319 6,988 Gross profit $ 1,388 $ 110 $ 1,498 Three months ended March 31, 2015 Revenue $ 985 $ 704 $ 1,689 Cost of revenue 798 488 1,286 Gross profit $ 187 $ 216 $ 403
Schedule of Geographic Information	Geographic information for revenue based on location of customer is as follows: Three Months Ended March 31, 2016 2015 North America $ 4,521 $ 1,271 All Other 3,965 418 $ 8,486 $ 1,689

Organization (Details Textual)

Organization (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Organization [Line Items]
Retained Earnings (Accumulated Deficit), Total	$ (95,042)		$ (91,391)
Cash and Cash Equivalents, at Carrying Value, Total	12,314	$ 21,133	$ 19,552	$ 25,190
Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total	(6,789)	$ (3,828)
Average Monthly Cash Burn	$ 1,800

Basis of Presentation and Sum33

Basis of Presentation and Summary of Significant Accounting Policies and Estimates (Details Textual) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		12 Months Ended
	Dec. 31, 2015	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Significant Accounting Policies [Line Items]
Reduction In Net Loss Attributable To Common Stock Holders		$ 2,358
Medical Device [Member]
Significant Accounting Policies [Line Items]
Reduction In Net Loss Attributable To Common Stock Holders				$ 2,358
Deferred Revenue, Revenue Recognized	$ 6,517			6,517
Cost of Revenue	$ 4,159			$ 4,159
Product Liability Accrual, Component Amount		212
Customer Advances and Deposits, Current, Total		$ 911
Minimum [Member] | Medical Device [Member]
Significant Accounting Policies [Line Items]
Revenue Maintenance Contractual Agreement Term	1 year	1 year
Maximum [Member] | Medical Device [Member]
Significant Accounting Policies [Line Items]
Revenue Maintenance Contractual Agreement Term	3 years	4 years
Sales Revenue, Net [Member]
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage		10.00%
Customer One [Member] | Accounts Receivable [Member]
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage		16.00%		10.00%
Customer One [Member] | Sales Revenue, Net [Member]
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage		27.00%	17.00%
Customer Two [Member] | Sales Revenue, Net [Member]
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage		20.00%	16.00%
Customer Three [Member] | Sales Revenue, Net [Member]
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage		11.00%
Customer Four [Member] | Sales Revenue, Net [Member]
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage		10.00%

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Liabilities:
Warrant liability	$ (6,210)	$ (9,195)
Fair Value, Measurements, Recurring [Member]
Liabilities:
Warrant liability	(6,210)	(9,195)
Contingent consideration liability	(768)	(768)
Quoted Prices in Active Markets for Identical Items Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Liabilities:
Warrant liability	0	0
Contingent consideration liability	0	0
Significant Other Observable Inputs Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Liabilities:
Warrant liability	0	0
Contingent consideration liability	0	0
Significant Unobservable Inputs Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Liabilities:
Warrant liability	(6,210)	(9,195)
Contingent consideration liability	$ (768)	$ (768)

Fair Value Measurements (Deta35

Fair Value Measurements (Details 1) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)
Derivative Financial Instruments, Liabilities [Member]
Balance at December 31, 2015	$ (9,195)
Gain on decrease in fair value of warrants issued with 2015 financing	2,985
Balance at March 31, 2016	(6,210)
Contingent Consideration [Member]
Balance at December 31, 2015	(768)
Gain on decrease in fair value of warrants issued with 2015 financing	0
Balance at March 31, 2016	$ (768)

Deferred Revenues (Details)

Deferred Revenues (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Deferred Revenue Arrangement [Line Items]
Deferred rental income	$ 64	$ 71
Deferred Revenue	1,988	8,573
Less current portion	1,222	3,960
Deferred revenues, non-current	766	4,613
Deferred medical device unit costs	255	4,590
Less current portion	(255)	(2,088)
Deferred cost of revenue, non-current	0	2,502
Customer deposits and advances [Member]
Deferred Revenue Arrangement [Line Items]
Deferred Revenue	47	48
Deferred Ekso medical device revenues [Member]
Deferred Revenue Arrangement [Line Items]
Deferred Revenue	551	7,388
Deferred extended maintenance and support [Member]
Deferred Revenue Arrangement [Line Items]
Deferred Revenue	$ 1,326	$ 1,066

Deferred Revenues (Details Text

Deferred Revenues (Details Textual) - Medical Device [Member] - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
	Dec. 31, 2015	Mar. 31, 2016	Dec. 31, 2015
Deferred Revenue Arrangement [Line Items]
Deferred Revenue, Revenue Recognized	$ 6,517		$ 6,517
Cost of Revenue	$ 4,159		$ 4,159
Maximum [Member]
Deferred Revenue Arrangement [Line Items]
Revenue Maintenance Contractual Agreement Term	3 years	4 years
Minimum [Member]
Deferred Revenue Arrangement [Line Items]
Revenue Maintenance Contractual Agreement Term	1 year	1 year

Intangible Assets (Details)

Intangible Assets (Details) $ in Thousands	Mar. 31, 2016USD ($)
Indefinite-lived Intangible Assets [Line Items]
Cost	$ 1,610
Accumulated Amortization	(179)
Net	1,431
Developed Technology Rights [Member]
Indefinite-lived Intangible Assets [Line Items]
Cost	1,160
Accumulated Amortization	(129)
Net	1,031
Customer Relationships [Member]
Indefinite-lived Intangible Assets [Line Items]
Cost	70
Accumulated Amortization	(8)
Net	62
Customer Trade Name [Member]
Indefinite-lived Intangible Assets [Line Items]
Cost	380
Accumulated Amortization	(42)
Net	$ 338

Intangible Assets (Details Text

Intangible Assets (Details Textual) - USD ($) $ in Thousands	Dec. 01, 2015	Mar. 31, 2016	Dec. 31, 2015
Indefinite-lived Intangible Assets [Line Items]
Business Combination, Contingent Consideration, Liability		$ 768	$ 768
Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year		404
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months		537
Finite-Lived Intangible Assets, Amortization Expense, Year Two		490
Equipois, LLC [Member]
Indefinite-lived Intangible Assets [Line Items]
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	$ 1,071
Business Combination, Contingent Consideration, Liability	$ 768
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total		$ 1,610
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life		3 years

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Accrued Liabilities [Line Items]
Salaries, benefits and related expenses	$ 1,563	$ 1,464
Maintenance	911	0
Warranty expense	216	0
Professional fees	158	257
Other	80	164
Total	$ 2,928	$ 1,885

Maintenance and Warranty (Detai

Maintenance and Warranty (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Beginning Balance	$ 0	$ 126
Additions for estimated future expense	1,166	0
Incurred costs	0	(17)
Other	0	0
Closing Balance	1,166	109
Current portion			$ 1,127	$ 109
Long-term portion			39	0
Total	0	126	1,166	109
Maintenance [Member]
Beginning Balance	0	0
Additions for estimated future expense	911	0
Incurred costs	0	0
Other	0	0
Closing Balance	911	0
Current portion			911	0
Long-term portion			0	0
Total	0	0	911	0
Warranty [Member]
Beginning Balance	0	126
Additions for estimated future expense	255	0
Incurred costs	0	(17)
Other	0	0
Closing Balance	255	109
Current portion			216	109
Long-term portion			39	0
Total	$ 0	$ 126	$ 255	$ 109

Maintenance and Warranty (Det42

Maintenance and Warranty (Details Textual) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)
Cost of Property Repairs and Maintenance	$ 911

Lease and Note Obligations (Det

Lease and Note Obligations (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
2016 - remainder	$ 68
2,017	60
2,018	37
2,019	37
2,020	22
Total minimum payments	224
Less interest	(18)
Present value minimum payments	206
less current portion	(81)	$ (80)
Long-term portion	125
Lease hold Improvement Note [Member]
Debt Instrument [Line Items]
2016 - remainder	36
2,017	20
2,018	0
2,019	0
2,020	0
Total minimum payments	56
Less interest	(2)
Present value minimum payments	54
less current portion	(45)
Long-term portion	9
Capital Lease Obligations [Member]
Debt Instrument [Line Items]
2016 - remainder	32
2,017	40
2,018	37
2,019	37
2,020	22
Total minimum payments	168
Less interest	(16)
Present value minimum payments	152
less current portion	(36)
Long-term portion	116
Operating Lease [Member]
Debt Instrument [Line Items]
2016 - remainder	350
2,017	248
2,018	91
2,019	91
2,020	89
Total minimum payments	$ 869

Lease and Note Obligations (D44

Lease and Note Obligations (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Debt Instrument [Line Items]
Operating Leases, Rent Expense, Net, Total	$ 96	$ 86
Lease Expiration Date	May 31, 2017
Capital Lease Obligations [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross	$ 166
Debt Instrument, Interest Rate, Stated Percentage	4.70%
Debt Instrument, Maturity Date	Jul. 1, 2020
Debt Instrument Minimum Monthly Payments	$ 3
Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross	$ 200
Debt Instrument, Interest Rate, Stated Percentage	7.00%
Debt Instrument, Maturity Date	May 31, 2017
Debt Instrument Minimum Monthly Payments	$ 4

Capitalization and Equity Str45

Capitalization and Equity Structure (Details) - $ / shares shares in Thousands	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Schedule of Capitalization, Equity [Line Items]
Merger/PPO Warrant Shares Outstanding	4,085	4,085
2015 Series A Preferred Warrants [Member]
Schedule of Capitalization, Equity [Line Items]
Exercise price	$ 8.75
Warrant term	5 years
Merger/PPO Warrant Shares Outstanding	2,122	2,122
Pre 2014 Warrants [Member]
Schedule of Capitalization, Equity [Line Items]
Exercise price	$ 9.66
Merger/PPO Warrant Shares Outstanding	88	88
2014 PPO and Merger [Member] | Placement agent warrants [Member]
Schedule of Capitalization, Equity [Line Items]
Exercise price	$ 7
Warrant term	5 years
Merger/PPO Warrant Shares Outstanding	426	426
2014 PPO and Merger [Member] | Bridge warrants [Member]
Schedule of Capitalization, Equity [Line Items]
Exercise price	$ 7
Warrant term	3 years
Merger/PPO Warrant Shares Outstanding	371	371
2014 PPO and Merger [Member] | PPO warrants [Member]
Schedule of Capitalization, Equity [Line Items]
Exercise price	$ 14
Warrant term	5 years
Merger/PPO Warrant Shares Outstanding	1,078	1,078

Capitalization and Equity Str46

Capitalization and Equity Structure (Details 1) - Binomial Lattice Option Pricing Model [Member] - Warrant [Member]	3 Months Ended
	Mar. 31, 2016$ / shares
Schedule of Capitalization, Equity [Line Items]
Current Share Price	$ 5.25
Conversion Price	$ 8.75
Risk-free interest rate	1.16%
Periodic rate	0.55%
Term (years)	4 years 8 months 23 days
Volatility of stock	75.00%

Capitalization and Equity Str47

Capitalization and Equity Structure (Details Textual) $ / shares in Units, shares in Thousands, $ in Thousands	1 Months Ended	3 Months Ended
	Dec. 31, 2015USD ($)$ / sharesshares	Mar. 31, 2016USD ($)shares
Class of Stock [Line Items]
Common Stock, Shares Authorized	71,429	71,429
Preferred Stock, Shares Authorized	10,000	10,000
Common Stock, Shares, Issued	15,027	15,604
Common Stock, Shares, Outstanding	15,027	15,604
Preferred Stock, Shares Issued	13	9
Preferred Stock, Shares Outstanding	13	9
Fair Value Adjustment of Warrants | $		$ 2,985
Warrants Not Settleable in Cash, Fair Value Disclosure | $	$ 9,195
Conversion of Stock, Shares Converted		4
Conversion of Stock, Shares Issued		566
Preferred Stock Dividends, Income Statement Impact | $		$ 3,124
Unamortized Warrant Discount | $		$ 7,221
Warrant [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	2,122
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 8.75
Warrants Term	5 years
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues	15
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	2,122
Gross Proceeds from Preferred Stock and Warrants | $	$ 15,000
Preferred Stock Convertible Conversion Price		7.07

Stock-based Compensation (Detai

Stock-based Compensation (Details) - 2014 Plan [Member] $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)$ / sharesshares
Options Outstanding
Stock Awards, Balance | shares	1,963
Stock Awards, Options granted | shares	145
Stock Awards, Options exercised | shares	(10)
Stock Awards, Options forfeited | shares	(110)
Stock Awards, Options cancelled | shares	(9)
Stock Awards, Balance | shares	1,979
Stock Awards, Vested and expected to vest | shares	1,851
Stock Awards, Exercisable | shares	1,062
Weighted-Average Exercise Price, Balance | $ / shares	$ 7.09
Weighted-Average Exercise Price, Options granted | $ / shares	5.55
Weighted-Average Exercise Price, Options exercised | $ / shares	2.73
Weighted-Average Exercise Price, Options forfeited | $ / shares	8.41
Weighted-Average Exercise Price, Options cancelled | $ / shares	10.11
Weighted-Average Exercise Price, Balance | $ / shares	6.91
Weighted-Average Exercise Price, Vested and expected to vest | $ / shares	0
Weighted-Average Exercise Price, Exercisable | $ / shares	$ 0
Weighted-Average Remaining Contractual Life (Years), Balance	7 years
Weighted-Average Remaining Contractual Life (Years), Vested and expected to vest	6 years 10 months 6 days
Weighted-Average Remaining Contractual Life (Years), Exercisable	5 years 2 months 23 days
Aggregate Intrinsic Value, Balance | $	$ 1,522
Aggregate Intrinsic Value, Vested and expected to vest | $	1,518
Aggregate Intrinsic Value, Exercisable | $	$ 1,464

Stock-based Compensation (Det49

Stock-based Compensation (Details 1)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%
Risk-free interest rate, minimum	1.24%	1.41%
Risk-free interest rate, maximum	1.78%	1.92%
Volatility	77.00%	73.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	5 years	6 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	10 years	10 years

Stock-based Compensation (Det50

Stock-based Compensation (Details 2) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	$ 1,574	$ 349
Sales and marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	232	132
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	231	54
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	$ 1,111	$ 163

Stock-based Compensation (Det51

Stock-based Compensation (Details Textual) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Total	$ 1,574	$ 349
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Total	59
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Total	774
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 4,640
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 9 months 18 days
Equity Incentive Plan 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	3,714
Common Stock, Capital Shares Reserved for Future Issuance	1,480

Commitments and Contingencies (

Commitments and Contingencies (Details Textual) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)
Future minimum annual royalties:
Supply Agreement ,Minimum Annual Price	$ 157
Contractual Obligation, Due in Next Fiscal Year	50
Royalty Agreement Terms [Member]
Future minimum annual royalties:
Contractual Obligation, Due in Next Fiscal Year	$ 50
Royalty Agreement Terms [Member] | Net sales [Member]
Future minimum annual royalties:
Royalty Percentage	1.00%
Royalty Agreement Terms [Member] | License fees [Member]
Future minimum annual royalties:
Royalty Percentage	21.00%
Royalty Agreement Terms [Member] | Sub-licensee net sales [Member]
Future minimum annual royalties:
Royalty Percentage	1.00%

Net Loss Per Share (Details)

Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Numerator:
Net loss applicable to common stockholders, basic and diluted	$ (6,775)	$ (4,115)
Denominator
Weighted-average number of shares, basic and diluted	15,388	14,542
Net loss per share, basic and diluted	$ (0.44)	$ (0.28)

Net Loss Per Share (Details 1)

Net Loss Per Share (Details 1) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	7,373	3,462
Options to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	1,979	1,496
Warrants for common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	4,085	1,966
Common stock issuable upon conversion of preferred shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	1,309	0

Net Loss Per Share (Details Tex

Net Loss Per Share (Details Textual) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)$ / shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Reduction In Net Loss Attributable To Common Stock Holders | $	$ 2,358
Reduction In Net Loss Per Share Attributable To Common Stock Holders | $ / shares	$ 0.15

Segment Disclosures (Details)

Segment Disclosures (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Segment Reporting Information [Line Items]
Revenue	$ 8,486	$ 1,689
Cost of revenue	6,988	1,286
Gross profit	1,498	403
Medical Devices [Member]
Segment Reporting Information [Line Items]
Revenue	8,057	985
Cost of revenue	6,669	798
Gross profit	1,388	187
Engineering Services [Member]
Segment Reporting Information [Line Items]
Revenue	429	704
Cost of revenue	319	488
Gross profit	$ 110	$ 216

Segment Disclosures (Details 1)

Segment Disclosures (Details 1) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Segment Reporting Information [Line Items]
Revenue	$ 8,486	$ 1,689
North America [Member]
Segment Reporting Information [Line Items]
Revenue	4,521	1,271
All Other [Member]
Segment Reporting Information [Line Items]
Revenue	$ 3,965	$ 418

Subsequent Event - Reverse St58

Subsequent Event - Reverse Stock Split (Details Textual)	May. 04, 2016
Subsequent Event [Member]
Subsequent Event [Line Items]
Stockholders' Equity, Reverse Stock Split	1-for-7 reverse split